(Q24243664)

2

object named as

Stefan Michiels

0 references

Thierry Le Chevalier

6

object named as

Thierry Le Chevalier

0 references

author name string

Catherine Delbaldo

1

0 references

Estelle Rolland

3

0 references

Nathalie Syz

4

0 references

Jean Pierre Pignon

Cochrane Database of Systematic Reviews

7

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Docetaxel Versus Docetaxel/Cisplatin in Patients with Advanced Non–Small-Cell Lung Cancer: Preliminary Analysis of a Multicenter, Randomized Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Combination chemotherapy of advanced lung cancer.A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

A prospective randomized trial of combination vindesine and cisplatin versus single-agent vindesine in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

A randomized phase II study of vinorelbine plus gemcitabine with/without cisplatin against inoperable non-small-cell lung cancer previously untreated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

New combinations in the treatment of lung cancer: a time for optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Treatment of advanced non-small-cell lung cancer with two-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Present and future treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Meta-analysis when only the median survival times are known: a comparison with individual patient data results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Confronting publication bias: a cohort design for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Is cisplatin still the best platinum compound in non-small-cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Meta-analysis of the literature or of individual patient data: is there a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Phase II trial of acivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004569.PUB2

7 January 2021

A randomized phase II trial of cisplatinum plus mitomycin-C plus vinorelbine and carboplatin plus vinorelbine in advanced non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD004569.PUB2

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD004569.PUB2

Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD004569.PUB2

Non-small cell lung cancer part: I Biology, diagnosis, and staging

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD004569.PUB2

Identifiers

DOI

10.1002/14651858.CD004569.PUB2

0 references

Fatcat ID

release_nbxb2k7oibhtbnn3umhju5sthm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nbxb2k7oibhtbnn3umhju5sthm

24 November 2022